China Shandong-based AccurDx Biotech announces the completion of a tens of millions of yuan Series A+ financing led by Shandong New Growth Drivers Fund for new product development and manufacturing facility expansion.

Founded in January 2017 in Jinan City, AccurDx Biotech is a high-tech company specialising in in-vitro diagnostic instruments and reagents, with offices in Beijing, Shanghai, Hangzhou and Suzhou. The company is dedicated to providing exquisite products and precise automated solutions for clinical diagnosis, covering coagulation detection system, specific protein detection system, reproductive detection system and immunoassay system.

In September 2022 AccurDx Biotech completed over 100 million yuan ($14.3 million) of Series A financing co-led by Addor Capital and CITIC Healthcare Fund.

In terms of diagnostic instruments, AccurDx Biotech has flexible automatic coagulation analysis line ADX-E1 designed for coagulation testing, automatic specific protein analyser CR-2000, automatic sedimentation analyser MT-1000, and automatic chemiluminescence immunoassay analyser AC-1000.

The fully automated coagulation analysers and supporting reagents independently developed by AccurDx Biotech have been used in more than 100 tier 3 hospitals in China. According to clinical feedback, these products have reached the level of international advanced similar products in terms of detection precision, result accuracy and test throughput.

The Post is Available in: English – 简体中文

Leave a Reply

Your email address will not be published. Required fields are marked *

en_GBEnglish (UK)